Exor: Fiat Crisis to Ferrari Glory - [Business Breakdowns, EP.229]

Summary

• Krishna Mohanraj of Diamond Hill frames Exor as the Agnelli family’s ~€45bn Dutch holdco trading at a 50–60% discount to NAV — roughly €100 a share against ~€180 of underlying value. 70% of gross assets sit in four listed names — Ferrari, Stellantis, CNH Industrial and Philips — and with the ex-Ferrari names at reasonable valuations, he argues the underlying NAV itself isn’t stretched: “with the exception of Ferrari, I wouldn’t call any of the other listed companies overly valued.”
• Ferrari has been “the gift that keeps on giving” — it drove essentially all recent NAV/share growth and swelled from 15% of the portfolio to nearly half — so Exor sold about $3bn of shares in February. The move acknowledged Ferrari’s outsized weight and signaled comfort with concentration only up to 25–30%, while proceeds were intended for buybacks and additional investments. Mohanraj says Exor’s own discounted stock is “hugely undervalued”: “what do they know better than Exor itself?”
• The discount debate is fair, per Mohanraj: strip out Ferrari and you’re left with “an odd collection of turnarounds in markets that have both cyclical and structural headwinds,” managed on a horizon longer than most investors want. The market’s implicit question — “why bother when you can own Ferrari directly… or if you want to play value, own Philips or CNH Industrial selectively” — makes the investment case dependent on a long time horizon and confidence in alignment between Elkann and minority shareholders. You should own it for NAV/share compounding, not a narrowing discount, “because that is not in management’s control.”
• John Elkann’s formation is the governance case: named heir at 21 in 1997, sole family representative at 27 after Fiat had gone through four CEOs in three years and looked close to collapse, he played a role in selecting outsider Sergio Marchionne — who got $2bn from GM to cancel a put option and turned Fiat around. That crisis helped establish the discipline of keeping debt at 10–20% of assets, mostly in long-duration bonds, so Exor can “play offense” and is “never at the mercy of creditors.”
• The stated framework is “building great companies with great people,” measured by NAV/share growth versus MSCI World — “act like an entrepreneur, but with a rock-solid balance sheet.” Exor plays “critical friend rather than an aggressive owner,” and its edge is people selection, insider or outsider alike: Marchionne, technical leader Benedetto Vigna at Ferrari, and homegrown Gerrit Marx at CNH Industrial.
• The next decade targets healthcare, luxury and technology — with healthcare technology “really the most promising area,” at least so far: a Philips stake increased from 17–18% to almost 20% with board presence, plus family-owned Institut Mérieux. Optionality is accumulating quietly: Lingotto asset management, with about 6.4bn in assets and partly arising from the PartnerRe/Covéa relationship, ventures investment Via (9% stake, confidential S-1 filed), and Elkann joining Meta’s board earlier this year for “a ringside view to AI.”
• The transferable lesson is decisiveness: no Buffett-style “thumb sucking,” but maybe two or three intentional portfolio-moving decisions a year. Long-term investors should ask “if we’re hiding behind the long term because we’re afraid of uncertainty” — and ultimately this is “definitely a bet on the jockey more than just on the current set of assets.”

Deep dive

1. A century of Fiat, told through three leaders — then simplified in 2009

• Mohanraj’s opening frame: Exor is “a Dutch company on paper, but in its bones it’s all Italian” — Fiat was Italy’s industrial engine through both world wars, held 80% of the Italian auto market, and put Italian design on the map with the 1957 Fiat 500. And the story is “still evolving”: “the Exor of twenty thirty-five, it’s not gonna look anything like the Exor of today.”
• The dynasty in three acts: founder Giovanni Agnelli, entrepreneur and senator for over two decades; grandson Gianni, who ran Fiat for nearly forty years, struck the Ferrari partnership — “a masterstroke for the family’s fortunes” — and was a global fashion icon; and John Elkann, nominated heir at 21 in a symmetry with his own grandfather’s grooming.
• Exor itself only dates to 2009, created to clean up a “complex mess” of holding companies (IFI, founded 1927, plus IFIL) into one Dutch-domiciled vehicle with capital-gains and dividend exemptions, a competitive tax rate, and global treaties.

2. Elkann inherited a crisis — and the Marchionne hire made everything else possible

• Context matters: Elkann became sole family representative in 2003–04, aged 27, after his grandfather’s and great-uncle’s deaths, with Fiat through four CEOs in three years and looking “like the firm won’t survive.” Yet his background fit — born in New York, schooled in the UK, Brazil and France, engineering in Turin, GE experience, four languages, and years as a “silent participant” on his grandfather’s business calls.
• His first big call was playing a role in selecting outsider Sergio Marchionne — controversial then, “brilliant” in hindsight. Marchionne got General Motors to pay ~$2bn to cancel a put option on Fiat’s auto business (“the last thing that GM wanted was to take on a struggling auto business”), cut costs, and had Fiat strong enough by the financial crisis to merge with Chrysler. Elkann still “pays homage to Sergio as both a personal mentor and a transformative figure.”
• The result: the conglomerate was broken into its pieces — Stellantis, CNH Industrial, Iveco, Ferrari — and perhaps three of the big four listed holdings in 2009 are gone, “so that tells you the extent of change.”

3. Ferrari is “not a car company” — and Exor just trimmed it anyway

• Today’s portfolio: ~€45bn gross asset value, 70% in four names — Ferrari, Stellantis, CNH Industrial and Philips; another 6–7% in Iveco, Juventus and Clarivate; the rest private (Louboutin, Shang Xia, The Economist, Welltec, Lingotto). In 2009 this was “predominantly a mass-market auto company”; now Stellantis is only 10–12% of assets.
• On Ferrari, Elkann’s line as relayed: “it’s not a car company… something beyond great” — the ethos is motor racing, “selling cars is almost an afterthought” — and the market agrees. Mohanraj thinks the EV transition will re-ask the question and likely reconfirm the answer, “but that is still TBD.”
• The stake ran from 15% of NAV to “almost half,” so February’s ~$3bn sale signals comfort at 25–30% concentration and that Exor finds its own discounted stock “hugely undervalued” — “what do they know better than Exor itself?” The proceeds are intended for buybacks and additional investments.

4. The legacy stack: cheap cyclicals, one family indulgence, one strategic sleeper

• Stellantis, CNH Industrial and Iveco belong together: cyclical, capital-intensive, in some phase of a turnaround. Stellantis “is definitely a car company… it is very clear that it’s trouble,” born of Marchionne’s overcapacity-consolidation thesis. CNH is the higher-quality asset — number two globally behind John Deere, with new insider CEO Gerrit Marx, a cyclical trough and undemanding valuation. Iveco has live catalysts: a defense spin-off or sale into “a lot of pent-up demand,” plus M&A chatter including Tata Motors.
• Juventus gets no varnish: a “legacy asset” with a “checkered recent history” — governance scandals forced the entire board including an Agnelli president to resign. “A fair question is, why bother? Isn’t it just a headache… The only possible reason it’s in the portfolio is because it’s a family passion. So it is what it is.”
• Clarivate — subscription analytics spun from Thomson Reuters — is “a lot more interesting”: Mohanraj sees it as a potential building block for the healthcare/technology ecosystem where Exor “wanna step into the future.”

5. The 50–60% discount: a fair debate, met with buybacks not complaints

• The math is simple — 70% listed, mark the rest from disclosures, subtract net debt — and “you don’t need to be too precise” because the discount is 50–60%, depending on assumptions (host: ~€180 NAV versus ~€100 stock).
• Why so wide? A holdco is “the exact opposite of a pure-play exceptional business”: NAV growth in the last three or four years, and even longer, has all come from Ferrari, and ex-Ferrari you’re left with “an odd collection of turnarounds… managed by a third party who acts with a time horizon that might be much, much longer than what most market participants want.” Hence: “why bother when you can own Ferrari directly?”
• Mohanraj admires Elkann’s response: “not defensive, not complaining that the market is wrong,” but treating the discount as “an amazing opportunity” to buy back stock. The investor’s contract: long horizon, faith in alignment, NAV/share growth — “you shouldn’t be in it hoping for a narrowing of the discount because that is not in management’s control.”

6. The duality: entrepreneurial spirit, non-negotiable financial discipline

• The framework: “building great companies with great people,” scored on NAV/share versus MSCI World. More than half their role is people — “thinking long term but acting in the now” — open to insiders and outsiders alike (Vigna, a technical leader not from automotive, chosen for his sensor and microelectronics patents to lead Ferrari into EVs), then playing “critical friend rather than an aggressive owner.”
• The balancing side is the one tenet “never compromised on in the last twenty years,” born of the family having to inject capital in the crisis: debt at 10–20% of assets, mostly long-duration bonds, five-to-six years. That buys a stable dividend, freedom from creditors, and the ability to play offense. “If you’re managing a family fortune for the very long term, it’s really the only way to do it.”
• PartnerRe is the case study in changing one’s mind: bought 2015 for $9bn on a Berkshire-style thesis that patient capital absorbs volatility better than public markets; elevated cat losses made returns “just okay” (maybe ~9–10% IRR), so when Covéa bid, “all right, let’s take the win and move on” — while Exor retained talent and a partnership that helped lead to Lingotto, with about 6.4bn in assets.
• Other private assets offer potential optionality beyond their current face values: The Economist is a marquee brand facing media and AI pressure; Institut Mérieux provides a long-term healthcare foothold; Louboutin is a patient-owner luxury investment; and Welltec is an energy-industry robotics and tools company.

7. 2035: healthcare tech ambitions, a Gianni maxim, and the decisiveness lesson

• The long-term sectors are healthcare, luxury and technology — but luxury is “a super small, crowded space” where the likelihood of finding anything at the right price is pretty low, and tech is early: the Vento seed program in Italy, ventures investment Via (2020 investment, ~9%, confidential S-1 recently filed), and Elkann joining Meta’s board earlier this year for “a ringside view to AI.”
• Healthcare technology is “really the most promising area,” at least until now: Philips — whose journey from conglomerate to pure-play health tech, complete with sleep-apnea recall, “has a lot of resonance with their own restructuring of Fiat” — with the stake increased from 17–18% to almost 20% plus a board seat, alongside Institut Mérieux. The hedge stays: “in healthcare, innovation takes much longer than people expect, and very often companies don’t get paid for innovation.”
• The governing quote, from Gianni via Elkann: “Groups like ours typically go through three stages in their development: a time of strength, a time of privilege, and a time of vanity. For me, the first is the only one that counts.”
• Mohanraj’s closing lesson: decisiveness — no “thumb sucking,” just maybe two or three intentional moves a year, a reflex learned when sticking with the status quo would not have allowed Fiat to survive. Long-term investors “tend to have a bias to no action” and should ask “if we’re hiding behind the long term because we’re afraid of uncertainty.” Ultimately: “definitely a bet on the jockey more than just on the current set of assets.”